The abstract is read at the publisher; the summary is JClub's.
Tovecimig plus paclitaxel improved RECIST v1.1 objective response rate and progression-free survival versus paclitaxel alone in 168 patients with advanced biliary tract cancer, with ORR 18.0% vs 5.3%.
- Why it matters: Patients with previously treated advanced biliary tract cancer have limited options and short overall survival, creating a need for more effective second-line therapies.
- What they did: In COMPANION-002, a randomized phase 2/3 trial, patients with advanced BTC and one prior systemic therapy received paclitaxel with or without tovecimig, with ORR by blinded independent central review as the primary endpoint.
- The result: Tovecimig plus paclitaxel increased PFS to 4.7 vs 2.6 months (HR 0.44; P < .0001) and improved post-progression PFS after crossover (3.5 vs 1.9 months; HR 0.40; P = .0035), while no OS difference was seen (HR 1.05; P = .779).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.